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Study Drug to Warfarin at the
End of the ENGAGE AF–TIMI 48 Trial
Setting a New Standard*John W. Eikelboom, MBBS,yzx Thomas Vanassche, MD,y Stuart J. Connolly, MDyzxI nterruption of warfarin treatment is associatedwith an increased risk of thromboembolic events(1). Among patients with atrial ﬁbrillation (AF)
receiving warfarin for stroke prevention, as many
as 1 in 10 temporarily interrupt treatment each
year, most commonly for invasive procedures (1,2).
Because of its long half-life, warfarin is usually
stopped 4 to 5 days before a procedure, and it takes
another 4 to 5 days after restarting treatment before
a therapeutic anticoagulant effect is regained. In or-
der to minimize the time off treatment and thereby
reduce the risk of thromboembolism around the
time of the procedure, the American College of
Chest Physicians guidelines recommend the use of
“bridging anticoagulation” with a rapid-acting paren-
teral anticoagulant for AF patients deemed to be
at high risk of stroke during temporary treatment
interruption (1).
Patients switching from a non–vitamin K antago-
nist oral anticoagulant (NOAC) to warfarin also are
at increased risk of thromboembolic events, and
this risk may be even higher when investigators*Editorials published in the Journal of the American College of Cardiology
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views of JACC or the American College of Cardiology.
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disclose.overseeing the switch are blinded to the prior treat-
ment (3,4). The ROCKET AF (Rivaroxaban Once daily
oral direct factor Xa inhibition Compared with
vitamin K antagonism for prevention of stroke and
Embolism Trial in Atrial Fibrillation) trial in-
vestigators (5) reported that patients with AF
switching from blinded rivaroxaban to open warfarin
at the end of the trial had a 3-fold increase in risk of
both stroke and major bleeding compared with those
switching from blinded warfarin to open warfarin
(Table 1) (3). The increase in stroke risk appeared to
be explained by a delay in achieving a therapeutic
international normalized ratio (INR) during the tran-
sition phase; at 30 days, only 52% of patients
switching from rivaroxaban to warfarin had $1 ther-
apeutic INR value compared with 83% of those who
switched from blinded to open warfarin (3).
The ARISTOTLE (Apixaban for Reduction In STroke
and Other Thromboembolic Events in Atrial Fibrilla-
tion) investigators (6) attempted to minimize the
risk of stroke during transition from blinded NOAC
treatment to warfarin at the end of the study by
recommending the use of a bridging kit that con-
tained a 2-day supply of apixaban (for patients
switching from blinded apixaban to open warfarin) or
a 2-day supply of placebo (for patients switching from
blinded warfarin to open warfarin) (4). Despite these
efforts, patients switching from apixaban to open
warfarin experienced an increase in thromboembolic
and bleeding events similar in magnitude to that seen
in the ROCKET-AF trial (Table 1).
The ENGAGE AF-TIMI 48 (Effective Anticoagulation
with Factor Xa Next Generation in Atrial Fibrillation–
Thrombolysis In Myocardial Infarction 48) is the most
recent blinded trial comparing an NOAC with
warfarin for stroke prevention in patients with AF
(7). Informed by the reports from the ROCKET-AF
TABLE 1 Rates of Stroke and Major Bleeding During the First 30 Days After the End of Blinded Trials Comparing Non–Vitamin K Antagonist Anticoagulant With
Warfarin for Stroke Prevention in Atrial Fibrillation
Trial
Transition Stroke Major Bleeding
Study NOAC
to Open
Warfarin
Study Warfarin
to Open
Warfarin
Study NOAC to
Open Warfarin
Study Warfarin
to Open
Warfarin
Hazard Ratio
(95% Conﬁdence
Interval)
Study NOAC to
Open Warfarin
Study Warfarin
to Open
Warfarin
Hazard Ratio
(95% Conﬁdence
Interval)
ROCKET 4,232
(92.2)
4,292
(92.2)
6.42 1.73 3.72
(1.51–9.16)
7.29 2.01 3.62
(1.56–8.36)
ARISTOTLE 5,723
(84.3)
5,570
(84.8)
4.02 0.99 4.06
(1.53–10.77)
4.97 1.97 2.5
(1.21–5.21)
ENGAGE AF–TIMI 48 3,107
(67.4)
3,147
(69.9)
1.57
(30 mg edoxaban)
1.94 0.81
(0.22–3.02)
3.93
(30 mg edoxaban)
2.71 1.45
(0.55–3.80)
3,050
(67.4)
2.80
(60 mg edoxaban)
1.03
(0.36–2.94)
1.60
(60 mg edoxaban)
0.83
(0.22–3.07)
Values are n (%) or %/yr.
ARISTOTLE ¼ Apixaban for Reduction In STroke and Other Thromboembolic Events in Atrial Fibrillation; ENGAGE AF–TIMI 48 ¼ Effective Anticoagulation with Factor Xa Next Generation in Atrial
Fibrillation–Thrombolysis In Myocardial Infarction 48; NOAC ¼ non-vitamin K antagonist oral anticoagulant; ROCKET ¼ Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K
antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation.
TABLE 2 End-of-Stu
ROCKET No
ARISTOTLE 2-day
(full-d
ENGAGE
AF–TIMI 48
14-da
(half-
INR ¼ international norma
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586and ARISTOTLE investigators of increased stroke
and bleeding during the ﬁrst 30 days after the end
of the trial, the ENGAGE AF–TIMI 48 trialists
implemented a rigorous plan for patients switching
from blinded anticoagulant to open warfarin at the
end of the trial (Table 2). As reported by Ruff et al. (8)SEE PAGE 576in this issue of the Journal, key features of the
ENGAGE end-of-study transition plan were a kit that
contained a 14-day supply of half-dose edoxaban
(for patients switching from blinded edoxaban to
open warfarin) or a 14-day supply of placebo (for
patients switching from blinded warfarin to open
warfarin), frequent INR testing during the transition
phase, and a standardized vitamin K antagonist
dosing algorithm to rapidly achieve a therapeutic
INR in patients switching from edoxaban to warfarin.
The ENGAGE AF–TIMI 48 end-of-study transition
plan appears to have worked very well; at 30 days,
98% of patients switching from edoxaban to warfarin
had $1 therapeutic INR value compared with 99% of
those who continued on warfarin, and patientsdy Strategy for Transitioning to Open Antithrombotic Treatment
Transition
Dosing Kit?
Duration of Use
of Transition Kit
INR Testing
Strategy
VKA Dosing
Algorithm
Not applicable No No
blinded transition kit
ose apixaban or placebo)
2 days No No
y blinded transition kit
dose edoxaban or placebo)
14 days or
until INR >2
Yes Yes
lized ratio; VKA ¼ vitamin K antagonist; other abbreviations as in Table 1.switching from blinded edoxaban to open warfarin
had similar rates of stroke and bleeding to those
switching from blinded warfarin to open warfarin.
The impressive results reported by Ruff et al. (8)
appear to set a new standard for the management of
patients transitioning from an NOAC to open warfarin
at the completion of blinded anticoagulation trials.
Their data also provide several valuable insights into
optimal management of patients who require inter-
ruption of anticoagulation in clinical practice. First,
the ﬁnding of similar event rates in patients tran-
sitioning from blinded edoxaban to warfarin com-
pared with those switching from blinded warfarin to
open warfarin supports the conclusion that bridging
anticoagulation, coupled with close INR monitoring
and algorithm-based warfarin dosing, is effective for
prevention of thromboembolic events. Second, the
lack of excess bleeding with the half-dose edoxaban
bridging regimen employed in the ENGAGE AF–TIMI
48 trial raises the possibility that lowering the dose
of the anticoagulant can improve safety without
compromising efﬁcacy. Previous observational studies
have consistently demonstrated that bridging with a
rapid-acting parenteral anticoagulant continued until
the INR reaches 2.0 is associated with an increased
risk of bleeding (9), most likely explained by over-
lapping of full therapeutic doses of bridging anti-
coagulation with warfarin (10). Third, despite the
success of the ENGAGE AF–TIMI 48 end-of-trial
transition plan, annualized event rates for stroke
during the transition phase were somewhat higher
than during the rest of the trial, reminding clinicians
that even when carefully managed, switching from
one anticoagulant to another is not without risk.
Key issues remain unresolved. Most patients in the
ENGAGE AF–TIMI 48 trial switching from edoxaban to
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587warfarin had a CHADS2 score #3, and it is unclear
whether bridging needs to be uniformly applied or
whether similar results can be achieved if bridging is
restricted to patients with higher CHADS2 scores.
Although the use of half-dose of edoxaban achieved
promising results, it remains to be demonstrated
whether lowering the dose, and in particular, the use of
a 15-mg dose of edoxaban, is as effective as full-dose
of edoxaban or whether half-dose of edoxaban is suf-
ﬁcient in all patients. We also do not knowwhether the
results of bridging with half-dose of edoxaban can be
extrapolated to other NOACs. Finally, evaluation of the
transition kit in the ENGAGE AF–TIMI 48 trial was not
randomized, and our conclusions regarding the efﬁ-
cacy and safety of this approach compared with nobridging or a more limited bridging strategy are based
on indirect comparisons across trials and cannot be
considered deﬁnitive. Several large-scale randomized
controlled trials testing the efﬁcacy and safety of
various anticoagulation bridging regimens for patients
requiring interruption of warfarin therapy for
an invasive procedure are currently ongoing (1), and
their results will help to further deﬁne the role of
bridging anticoagulation in patients at risk of throm-
boembolic events during interruption of treatment.
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